Coulter Partners places Non-Executive Director for Erytech.
Coulter Partners was delighted to partner with Erytech Pharma to secure the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur). ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY) is a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. As censeur, Ms. Diaz will initially attend all Board of Directors meetings in an advisory capacity. ERYTECH will nominate Ms. Diaz to serve as a voting Board member in January 2017 in anticipation of the next general shareholders’ meeting.
|“Allene’s extensive experience in the biopharmaceutical industry, and oncology specifically, will be invaluable to us at this important stage of our clinical development. We thank everyone on the team at Coulter Partners for conducting such an outstanding search on our behalf. It is with great pleasure that we welcome Allene to our Board of Directors and we look forward to leveraging her strategic counsel as we work towards advancing our ERYCAPS technology platform-based products,”
Gil Beyen, Chief Executive Officer and Chairman of the Board of ERYTECH Pharma.
Ms. Diaz has more than 20 years of experience in the global biopharmaceutical and biotechnology industry and has held management and executive positions at leading biopharmaceutical companies, including TESARO, Merck Serono, Biogen Idec and Pfizer. With broad cross-functional expertise in sales, medical affairs, marketing, new product planning, portfolio planning, strategic planning, and market access, Ms. Diaz currently serves as Senior Vice President, Global Commercial Development at TESARO. She focuses on the development of commercialization strategies across therapeutic assets, evaluates the commercial impact of clinical development options, and assesses potential in-licensing opportunities. Prior to joining TESARO, Ms. Diaz served as Senior Vice President, Managed Markets at EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, where she developed market access strategies and tactics for reimbursement by commercial and government payers across the EMD Serono portfolio. Previously, Ms. Diaz also held the positions of Senior Vice President, Head of Oncology Commercial, U.S. and Vice President, Oncology Marketing at EMD Serono, where she oversaw the commercial pre-launch efforts for EMD Serono’s oncology products. Ms. Diaz has held executive, management and/or line positions at other leading companies including Amylin Pharmaceuticals, Cancervax Corporation, Biogen Idec, Pfizer, and Parke-Davis Pharmaceuticals.